Assessing the Utility of Test-Based Prediction Models: Heart Failure as an Example

Thomas A Trikalinos1

  • 1Departments of Health Services, Policy, and Practice and Biostatistics, Brown University School of Public Health, Providence, RI.

NEJM Evidence
|February 6, 2024
PubMed

Insights

Endotrophin levels strongly predict mortality in heart failure with preserved ejection fraction (HFpEF). This finding offers new insights into HFpEF pathophysiology and aids in risk prediction for patients and healthcare.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Research

Background:

  • Investigated the association between endotrophin levels and clinical outcomes in patients with heart failure with preserved ejection fraction (HFpEF).
  • Utilized data from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial subset and external datasets for validation.

Discussion:

  • Endotrophin levels show a significant correlation with all-cause mortality and a composite outcome in HFpEF patients.
  • The study establishes endotrophin as a potential prognostic biomarker in HFpEF.

Key Insights:

  • Demonstrated a strong link between endotrophin and adverse outcomes in HFpEF.
  • Validated the prognostic utility of endotrophin across different patient cohorts.

Outlook:

  • Endotrophin-based risk prediction can benefit patient management and healthcare systems.
  • Further research can explore endotrophin's role in HFpEF pathophysiology and therapeutic strategies.